Mining of the human genome has revealed approximately 7000 novel proteins, which could serve as potential targets for the development of novel therapeutics. Of these, approximately 2000 are predicted to be G-protein coupled receptors. Within this group of proteins, a family of 18 mammalian receptors has recently been identified that appear to exhibit selectivity toward the so-called trace amines. The trace amines are a family of endogenous compounds with strong structural similarity to classical monoamine neurotransmitters, consisting primarily of 2-phenylethylamine, m-and ptyramine, tryptamine, m-and p-octopamine and the synephrines. The endogenous levels of these compounds are at least two orders of magnitude below those of neurotransmitters such as dopamine, noradrenaline and 5-HT. The effects of these low physiological concentrations have been difficult to demonstrate but it has been suggested that they may serve to maintain the neuronal activity of monoamine neurotransmitters within defined physiological limits. Such an effect of trace amines would make them ideal candidates for the development of novel therapeutics for a wide range of human disorders. Although the demonstration of a trace amine family of receptors has seen a resurgence of interest in these endogenous compounds, with recent articles reviewing trace amine pharmacological and physiological responses, the potential clinical utility of the trace amine receptors has not been specifically addressed. Historically, trace amines have been implicated in a diverse array of human pathologies ranging from schizophrenia to affective disorders to migraine. Recent studies have strengthened some of this historical data by linking trace amine receptor polymorphisms and mutations to distinct clinical conditions. The aim of the current article is to review the previous studies linking trace amines to human pathology in the context of the recently discovered trace amine receptors and evidence of the existence of trace amine receptor polymorphisms and mutations associated with such disorders. In addition, recent evidence linking trace amines to the development of drug dependence will be discussed.
INTRODUCTION
Trace amines are a family of endogenous monoamine substances structurally closely related to the monoamine neurotransmitters. Members of this family include 2-phenylethylamine (PE), p-and m-tyramine, tryptamine, pand m -octopamine and the synephrines. Although the presence of these compounds in all mammalian species has been known for several decades, it is only within the last five years that they have become a focus of the mainstream scientific community. This has coincided with the discovery of a family of receptors [1, 2] , at least some of which are selectively activated by the trace amines. This resurgence of interest in the trace amines is evidenced by a number of recent review articles dealing primarily with possible physiological and pharmacological relevance of the trace amines [3] [4] [5] [6] . Whilst providing a basis for future studies concerning the basic molecular action and function of trace amines, these reports have largely neglected a large body of historical data linking changes in trace amine metabolism to a number of disorders. The purpose of the current article is to review the historical data linking trace amines to human disorders in the context of the recent discovery of trace amine receptors. Prior to describing the evidence for a role of trace amines in various disorders, the current state of trace amine physiology and pharmacology will briefly be outlined in order to provide a context for subsequent discussions.
Trace Amine Receptors
The trace amine receptor family, initially identified by Borowsky et al. [1] and Bunzow et al. [2] , is a family of Gprotein coupled receptors. It is worth emphasizing, however, that thus far only two members of this family have been shown to be responsive to trace amines [1, 2, 7, 8] and an endogenous ligand for each receptor has yet to be unequivocally identified. Suggested endogenous ligands beyond the trace amines include the O-methyl monoamine metabolites [2] , thyronamine metabolites of thyroid hormone [9] and imidazoline ligands [10] including the β-carbolines [3] . On this basis, Lindemann et al. [11] suggested the receptors to be re-named as trace-amine-associated receptors (TAAR) and considering both phylogenetic relationships and predicted homology of the ligand recognition pocket, proposed a uniform nomenclature. This proposed nomenclature will be used in the current article. Table (1) relates this nomenclature to previously used names of the trace amine receptors.
Whilst there are up to 18 TAAR in the rodent genome, two of which are pseudogenes, the human genome contains only 9 TAAR genes, out of which 3 are pseudogenes ( Table  2) . Indeed, the pronounced inter-species variability documented for TAAR ( Table 2 ) has prompted the suggestion that they are intricately linked to fundamental species-specific functioning [5, 11] , and as such they are of possible relevance to disorders uniquely associated with humans. In each species, however, there appears to be three distinct sub-families of TAAR, with at least one member of each sub-family present in each species so far examined ( Table 2) .
Trace Amine Metabolism
The synthesis and metabolism of trace amines are directly analogous to that of the monoamine neurotransmitters ( Fig. 1 and 2) . Similar to the classical neurotransmitter amines, dopamine (DA), noradrenaline (NA) and 5-hydroxytryptamine (5-HT), the trace amines are synthesized in neuronal terminals in a process involving decarboxylation of precursor amino acids by the enzyme aromatic L-amino acid decarboxylase (AADC; EC 4.1.1.28) [12] . With respect to DA, NA and 5-HT synthesis, AADC is present in a large excess [13, 14] . Unlike the situation with DA, NA and 5-HT however, AADC is de facto, the rate limiting step in trace amine synthesis, being the only enzyme involved in the synthetic process, at least with respect to PE, tyramine ( Fig. 1) and tryptamine (Fig. 2) . As such, whilst alteration of AADC activity is expected to have little effect on brain levels of DA, NA and 5-HT, trace amine levels can be profoundly altered.
Metabolism of trace amines takes place in both glia and neuronal terminals predominantly via monoamine oxidases (MAO; EC 1.4.3.4), with PE being one of the few endogenous compounds exhibiting pronounced selectivity toward MAO-B [15] . Other trace amines show markedly reduced selectivity, with approximately equal affinities toward MAO-A and MAO-B [12] . Such metabolism results in the generation of the acid metabolites phenylacetic acid, hydroxyphenylacetic acid and hydroxymandelic acid for PE, the tyramines and octopamines, respectively. Tryptamine is metabolized to the corresponding acid indole-3-acetic acid.
Extraneuronal synthesis and metabolism of trace amines are also possible and indeed probable. For example, it is known that AADC is located outside the neuronal terminals in a number of peripheral tissues (see [13] and references therein). Likewise, MAO-B is well documented to be present in a number of extraneuronal peripheral tissues including platelets (see [16] and references therein). In this respect, it is also worth noting that a number of other amine oxidases are present in the plasma and the trace amines are substrates for at least some of these [17] . The relevance of such extraneuronal synthesis and metabolism of trace amines to their neuronal functioning has not been specifically studied and will not be considered further here. Notwithstanding, the relevant acid metabolites of trace amines remain the major metabolic end-product. Excretion of the unmetabolized trace amines and their acid metabolites occurs via the urine, with conjugated and unconjugated derivatives identified [18] [19] [20] [21] .
Trace Amine Physiology/Pharmacology
A detailed discussion of the physiological and pharmacological functions of trace amines in mammalian species is beyond the scope of the current article and the reader is referred to a number of recent thorough review articles [3] [4] [5] [6] . Of note, trace amines do not appear to be released in an activity-dependent manner from neurons, readily crossing cell membranes by simple diffusion [12] . Further, at physiological levels, trace amines do not appear to alter neuronal excitability. Rather, they appear to alter neuronal responsivity primarily to monoamine neurotransmitters [3, 12] , although a recent study has suggested a similar effect on GABA [22] . As shown in Table  ( 3), there is evidence that selectivity exists with respect to trace amines potentiating neurotransmitter responsivity. This has led to the suggestion that, rather than being neurotransmitters per se in mammalian species, the trace amines represent a new class of neuroactive compounds i.e, the neuromodulators [3, 12] . At supra-physiological levels, trace amines, and in particular PE have well documented amphetamine-like effects [23] [24] [25] . Indeed, PE has been TAAR7d  TA15   c   TAAR7e  TA14   c   TAAR7f  TA13P   c   TAAR7g  TA9   c   TAAR7h  TA6   c   TAAR7i  -TAAR8  TRAR5  a , TA5  a , TAR5  a , GPR102   a   TAAR8a  TA11   c   TAAR8b  TA7   c   TAAR8c  TA10   c   TAAR9  TRAR3  a , TA3  a,c , TAR3   a Unified nomenclature is that proposed by Lindemann et al. [11] .
-Receptor gene not previously named. a Gene nomenclature previously used in human, b Gene nomenclature previously used in chimpanzee, c Gene nomenclature previously used in rat, d Gene nomenclature previously used in mouse Group 1  TAAR1  TAAR2   TAAR1  TAAR1  TAAR2  TAAR3  TAAR4   TAAR1  TAAR2  TAAR3  TAAR4   Group 2  TAAR5  TAAR5  TAAR5  TAAR5   Group 3  TAAR6  TAAR8  TAAR9   TAAR6  TAAR6  TAAR7a, 7b, 7c, 7d, 7e, 7g,  7h  TAAR8a, 8b, 8c  TAAR9   TAAR6  TAAR7a, 7b, 7d, 7e, 7f TAAR8a, 8b, 8c TAAR9 Pseudogenes  TAAR3  TAAR4  TAAR7   TAAR2  TAAR3  TAAR4  TAAR7  TAAR8  TAAR9 TAAR7f, 7i TAAR7c
Although the above receptors have been identified in the genome of various mammalian species, the assumed associated receptor proteins have not necessarily been identified.
Fig. (1).
Relationship between monoamine neurotransmitter and trace amine metabolic pathways. Hydroxylation of L-phenylalanine can yield either p-or m-isomers of tyrosine. Although not shown in the figure, the same relationship exists between m-isomers and monoamine neurotransmitters as that shown for p-isomers. Note that in extraneuronal tissue, hydroxylation to tyrosine can also occur via the enzyme phenylalanine hydroxylase. Interconversion between subsequent p-and m-isomers of trace amines does not appear to occur. Interconversion of 2-phenylethylamine to p-and m-tyramine and the tyramines to dopamine does not appear to occur to a significant degree [197] . The putative interconversion of the octopamines and synephrines to noradrenaline and adrenaline respectively has not been investigated.
Fig. (2).
Relationship between indoleamine neurotransmitter and trace amine metabolic pathways. The putative interconversion of tryptamine and 5-hydroxytryptamine has not been investigated. suggested to be an endogenous amphetamine [26, 27] . Whether the levels of trace amines can be elevated sufficiently to achieve such effects in any but the most extreme of pathological situations requires further study.
The proposal that trace amines function as endogenous neuromodulators deserves further comment. In invertebrates, there is little doubt that trace amines function as true neurotransmitters [28, 29] . That such a situation is not readily generalizable to mammalian species is supported by studies of the phylogenetic relationships of trace amine receptors between vertebrates and invertebrates. Consistent with trace amines serving a different function in vertebrate species, invertebrate and mammalian trace amine receptors arose independently during evolution [1, 11, 30] . As indicated above, the high species variability in trace amine receptors has prompted the suggestion that the endogenous ligands for these receptors may be involved in speciesspecific functioning/adaptation [5, 11] . In agreement with this, it has recently been reported that TAAR present in the olfactory epithelium function in the recognition of urinary behavioral cues in the mouse [8] . Such a situation intuitively suggests that trace amines may be implicated in higher cognitive functions in humans and as such disorders associated with such functioning. As will be seen, this provides an interesting link to older studies examining changes in trace amine metabolism in various disease states. The strongest evidence for such a link was found in patients diagnosed with either affective or schizophrenic disorders (see later sections). Finally, if trace amine receptors are proven to be targets for endogenous neuromodulators, rather than neurotransmitter substances, this may have implications for the identification of the endogenous ligand(s). A neuromodulator substance, as previously defined [3] , requires the presence of a suitable neurotransmitter for its effect to be seen. Thus, when examining for substances that cause activation of trace amine receptors, traditional second messenger-related assays may be unsuitable, unless combined with activation of a partner neurotransmitter receptor. Further, such a situation has implications for the way in which trace amines are viewed with respect to disease conditions. Under a neuromodulator model, a given trace amine may be therapeutically useful in any disorder associated with an alteration in the partner neurotransmitter functioning, in addition to disorders associated with a primary alteration in trace aminergic functioning. As such, alterations in trace amine functioning as the underlying cause of a disorder are not necessarily required in order for receptor ligands to be therapeutically important. Thus, trace amine receptor ligands may be useful in alleviating symptomatology without addressing the underlying disease pathology.
Such therapeutic potential of TAAR has been recognized by a number of pharmaceutical companies conducting active trace amine research projects [6, 11] . At present, however, information on novel ligands showing selectivity at TAAR is not available through either the patent databases or within the scientific literature. The one exception to this is the demonstration that putative thyroid hormone metabolites and their synthetic derivatives are good TAAR ligands [9, 31] . Such activity was initially suggested to be of importance for the non-genomic actions of thyroid hormone, although the authors have recently presented an alternative explanation of such effects that do not appear to involve trace amines [32] . In addition, the compounds previously described by Knoll and colleagues [33, 34] , along with a series of trace amine derivatives synthesized by Ling et al. [35] are potential TAAR ligands. Although neither of these classes of compound appear to have been examined for efficacy at TAAR, their strong structural similarity to trace amines suggests that such studies are warranted.
Trace Amine Detection Assays
The following sections contain, in part, a review of older literature in which changes in trace amines and their metabolites were examined in various body tissues. Due to their trace concentrations and close structural similarity to the much more abundant monoamine neurotransmitters, assays for such measurements require a very high degree of selectivity and sensitivity. Although such assays have subsequently been developed (for example [36, 37] ), most of the earlier studies relied on assays with insufficient sensitivity and selectivity, resulting in a considerable overestimation of trace amine levels, confounding the interpretation of data. A discussion of the advantages and disadvantages of the various procedures that have been used to estimate trace amine levels in body tissues is beyond the scope of the current article and the reader is referred to previous review articles for a more detailed discussion [38, 39] . Although some of these earlier studies have been included in the following sections, care has been taken to limit this to studies which have subsequently been verified with more selective and sensitive assay procedures. While techniques for the determination of trace amine levels at the level of a single cell have not yet been described, those described by Durden and Davis [37] and Henry and colleagues [36] appear sufficiently sensitive and selective to allow the determination of trace amine levels in discrete brain nuclei through the use of in vivo microdialysis.
The following sections will review evidence and the rationale behind the potential utility of TAAR ligands in various disorders. Fig. (3) shows a schematic of the relevant trace amine associated proteins and compounds that will be discussed in subsequent sections.
PHENYLKETONURIA
Phenylketonuria is the most frequent of the so-called inborn errors of metabolism. It is an autosomal recessive condition characterized by a deficiency in phenylalanine hydroxylase activity, with a resultant marked elevation of peripheral phenylalanine and decreases in tyrosine levels. If left untreated, the disease results in a pronounced mental retardation, seizures and neurological and psychiatric dysfunction [40] . Although all of these may be related to the perturbation of normal CNS monoaminergic neurotransmitters due to the alteration of phenylalanine metabolism as a result of increased CNS phenylalanine availability (see Fig.  1 ), the mechanism of cognitive abnormalities remains unresolved [40] . As can be seen in Fig. (1) , increased brain levels of phenylalanine also result in an increase in PE levels. Such changes in PE levels result in altered neuronal functioning. Since PE exists in a steady state, with release from neuronal terminals occurring by simple diffusion, there is no opportunity for such increases in PE to be buffered by storage mechanisms, resulting in an increase in PE mediated stimulation of TAAR. Indeed, a marked increase in PE turnover has been observed [41, 42] , which was previously suggested as a possible cause of at least some of the neurological/psychiatric symptomatology observed [41] . Further, changes in other trace amine levels may also occur [43] . The possible relevance of trace amines to the development of seizure activity and epilepsy is detailed in subsequent sections.
Current treatment of phenylketonuria is restricted to dietary restriction of phenylalanine and supplementation with tyrosine. Even with early diagnosis and instigation of such a dietary regime, evidence of abnormal cortical functioning persists. Further, patients are required to maintain such a diet for life [40] . Although initially relaxation of dietary restriction was recommended beyond early childhood, evidence now exists that such dietary relaxation may be contraindicated and associated with subtle changes in cognitive functioning [40] . Antagonists or partial agonists of the cognate PE receptor may allow for such dietary relaxation whilst preventing the subsequent decline in functioning. Whether such PE receptor ligands could improve daily functioning beyond that currently seen with dietary restriction warrants investigation upon the development of such ligands.
SCHIZOPHRENIA
The potential role of trace amines in schizophrenia is one of the most well documented of the putative pathological indications. Indeed, the similarity of some phenylketonuric symptoms to those of paranoid schizophrenia has previously been documented [44] . As previously stated, TAAR has been suggested to be involved in responses unique to the human lifestyle [5] and anectodal evidence suggests that psychoses show a vastly greater preponderance in humans than in other primate species [45] . Much of the early interest in the possible role of trace amines in schizophrenic conditions stemmed from the close structural similarity of trace amines and in particular PE, to amphetamine. Amphetamine overdose and chronic use are known to induce paranoid schizophrenia-like symptoms. PE is structurally similar and has well documented amphetaminergic effects in animals, including induction of similar stereotyped behaviors [46] [47] [48] . On this basis, PE has been suggested to be an endogenous amphetamine [26, 27, 49] . This observation has been reinforced in recent years with the demonstration that amphetamine-type hallucinogens activate TAAR family members [2] . It is worth remembering, however, that in order for amphetaminergic effects to be seen with PE, levels need to be far in excess of those seen physiologically [3, 50] , which calls into question the likelihood of the involvement of TAAR. Further there is evidence that behavioral responses to such supra-physiological levels of PE are not identical to those seen with amphetamine [50] . The possibility, however, that some of the effects of the amphetamines may be mediated through an interaction with one or more TAAR deserves further study.
There is a wealth of older literature implicating alterations in trace amine metabolism and, in particular PE, to schizophrenia. A comprehensive review of these studies is beyond the scope of the current article and the reader is referred to the extensive tabulations previously compiled by Davis [18] . Here the salient features of these studies will be outlined to provide a historical context to the more recent studies implicating mutations in various proteins of relevance to trace amine metabolism to schizophrenia. A word of caution is warranted before beginning. Studies involving detection of changes in the levels of endogenous compounds such as the trace amines and their metabolites are inherently difficult to interpret. For instance, an increase in urinary excretion of a compound can equally easily be argued to represent a functional deficit in that compound (due to the increased excretion) or to represent a functional overactivity of the same compound (with the increased excretion reflecting the increased circulatory levels, due to the body being 'flooded' with the molecule of interest). Thus, changes in body fluid levels of trace amines are presented here merely to be indicative that an alteration in trace amine metabolic processes appears to be occurring. Where possible, corollary evidence will be outlined to indicate in which direction this change in metabolism may occur. The situation is complicated further in schizophrenia. It is now accepted that schizophrenia represents a complex family of disorders [51] rather than a single disease entity. Fig. (3) . Schematic representation of trace amine associated proteins and compounds. Abbreviations: Phe -L-phenylalanine, MAmonoamine, COMT -catechol-O-methyltransferase, TH -tyrosine hydroxylase, Tyr -tyrosine, TA -tyramine, OHPAA -hydroxyphenylacetic acid, DBH -dopamine-β-hydroxylase, OA -octopamine, PNMT -phenylethanolamine-N-methyl transferase, SYN -synephrine, PAA -phenylacetic acid. Other abbreviations are as defined in the text. For purposes of clarity, tryptamine specific pathways have been omitted. While some enzymes may exist in multiple cellular locations, for clarity only the predominant location has been shown. Although TAAR has the expected 7 putative transmembrane domains, available evidence suggests that TAAR may be primarily intracellular receptors.
As such, multiple causative factors are likely and even a common symptomatology cannot necessarily be taken to represent a common underlying pathology. Further, studies of patients with schizophrenia are difficult to control with respect to medication status. Indeed, studies often do not report the medication status of the patients involved. This further complicates attempts to interpret various studies with respect to each other.
An increased urinary excretion of PE has most frequently been reported in paranoid schizophrenia [18, 42, 52, 53] , although urinary PE changes appear less clear in nonparanoid forms of schizophrenia [18, 54] . A corresponding decrease in the urinary level of the main PE metabolite phenylacetic acid (PAA) has also been observed. However, other studies have reported increases in cerebrospinal fluid (CSF) PAA [18, 44] . Plasma PE levels have also been reported to be increased during acute phases of the disease [55, 56] . The sum total of such effects has been taken as supportive of the hypothesis that an increased PE activity plays a role in schizophrenia [49] . Similarly, altered metabolism of tyramine and tryptamine in schizophrenia has been suggested [43] . Indeed, urinary tryptamine levels have been shown to correlate with disease severity [18, 57] . Further, the plasma levels of the tyramine metabolite hydroxyphenylacetic acid have been reported to be decreased [18] . Trace amines other than PE, and their metabolites have, however, received relatively little investigation and some of the results have been questioned [58] .
Methylated tryptamines have also been implicated as playing a role in the onset of schizophrenia (see [59] for a historical perspective). N,N-dimethyltryptamine (DMT), a known, potent hallucinogen is produced endogenously in humans (see Fig. 2 ), although the physiological role of this trace amine derivative has been the subject of much debate [59] . Of interest is the fact that DMT is a good ligand for TAAR [2] . A number of studies have provided evidence for an increased urinary level of DMT associated with at least a sub-group of schizophrenia patients [60] [61] [62] . Such results promoted suggestions that acute episodes of schizophrenia were associated with endogenous DMT production. Lack of progress in defining a physiological role and the site of action for DMT, however, has hindered further research.
The relevance of trace amines to schizophrenia received considerable theoretical support following mapping of the TAAR genes. All TAAR map to chromosome 6q.23 [1, 2] . This region is within the previously identified SCZD5 schizophrenia locus, which is one of the most frequently replicated schizophrenia susceptibility loci [63] [64] [65] [66] [67] . TAAR genes appear to be rapidly evolving (mutating) [5] and TAAR polymorphisms have been identified [5, 11] . One such polymorphism in the TAAR2 gene has, in a preliminary study, been suggested to be associated with schizophrenia [68] . The TAAR6 gene maps particularly close to the SCZD5 locus [5, 11] and has received particular attention. Although initial studies suggested a linkage of TAAR6 polymorphisms to schizophrenia in patients of European and African-American ancestry [69] , this was not replicated in subsequent studies with patients of different ethnicities [70] [71] [72] . Further supporting a possible role for trace amines and their receptors in schizophrenia is the observation that TAAR6 is preferentially localized to the brain regions implicated in schizophrenia [69] .
Alterations in the activity and expression of enzymes involved in trace amine metabolic pathways have also been implicated in the etiology of schizophrenia. In particular, catechol-O-methyl transferase (COMT; EC 2.1.1.6) and AADC have been implicated. With respect to COMT, an enzyme variant associated with decreased activity, which shows a high transmittance in schizophrenia has been identified [73] [74] [75] [76] [77] . These observations take on greater significance with the observation that the O-methyl metabolites of monoamine neurotransmitters are particularly effective TAAR ligands [2] and are candidates to act as endogenous ligands at one or more TAAR. Consistent with such a role of COMT in the etiology of schizophrenia, the Omethyl metabolites of monoamines have been reported to be altered in the CSF of patients with various psychiatric conditions including schizophrenia [78] .
Numerous reports have linked schizophrenia with alterations in the trace amine synthetic enzyme AADC. A splice variant in AADC has been reported [79] , which has been hypothesized to be related to schizophrenia [6] . Polymorphisms of the AADC gene have been reported to be associated with the age of onset of schizophrenic disorders [80] , although a later study reported no association between AADC polymorphisms and schizophrenia [81] . More direct evidence has been provided of increased AADC activity present in various brain regions of drug-naïve schizophrenia patients [82, 83] . Similarly, the A1 allele of the D2 receptor, which has been suggested to be a risk factor for schizophrenia [84] , is associated with an increase in AADC activity [85] . As previously described, such increases in AADC activity would be expected to result in an increase in the steady state levels of trace amines without affecting the levels of the monoamine neurotransmitters. This provides a consistent link to the previously described hypothesis of increased PE levels causing schizophrenia. It is interesting to note that, at least in rodents, brain AADC levels are reported to increase from birth up to adulthood and then subsequently decrease [86, 87] . Whether a similar ontogeny of AADC expression occurs in humans requires investigation, but it raises the intriguing possibility of the maximal AADC level correlating to the age of maximal risk of developing schizophrenia. It should be noted however that genetic deficiencies in the PE metabolism enzyme MAO-B, which, in experimental animals, markedly elevate steady state PE levels whilst leaving monoamine neurotransmitter levels unaffected [88, 89] , are not associated with a human clinical phenotype [90] .
The preceding studies are in general, consistent with an over-activity of trace amine systems being involved in the pathogenesis of schizophrenia (Fig. 4) . Other studies, however, appear contradictory, in particular to the findings of increased AADC in patients with schizophrenia. Numerous studies from independent groups have reported that administration of a number of neuroleptic compounds results in acute increases in AADC activity in multiple brain regions in experimental animals [13, 91, 92] . Similarly, chronic administration of neuroleptics results in an increase in AADC mRNA [93, 94] , whilst various pharmacologically unrelated chemicals, all of which are associated with the onset of psychoses in humans, result in a decrease in AADC mRNA [94] . How such discrepancies can be resolved is unclear, although they may simply reflect species differences.
It has been reported that there is a decrease in the number of CNS D-neurons associated with schizophrenia [95] . Dneurons are groups of neurons that whilst containing AADC, appear neither to contain tyrosine hydroxylase, nor to synthesize 5-HT [96] [97] [98] . Such neurons are ideally suited to synthesize trace amines. Interestingly, reports suggest that there is a greater preponderance of D-neurons in humans than in rodents and they are particularly enriched in brain regions implicated in schizophrenia [99] . Such observations would appear to be consistent with the suggestion that TAAR are involved in species-specific adaptation responses. These reports of decreases in D-neuron numbers are suggestive of a decrease in trace aminergic functioning, playing a role in schizophrenia. Notwithstanding the apparent discrepancies, the above studies emphasize the importance of conducting studies in drug-naïve patients. The demonstration that neuroleptics alter AADC activity and levels in experimental animals makes it difficult to interpret studies conducted in patients receiving neuroleptic therapy.
ATTENTION DEFICIT/HYPERACTIVITY DISORDER
Although there is little direct evidence, changes in trace amines, in particular PE, have been identified as a possible factor for the onset of attention deficit/hyperactivity disorder (ADHD) [5, 27, 43, 78] . PE has been shown to induce hyperactivity and aggression, two of the cardinal clinical features of ADHD, in experimental animals [100] . Hyperactivity is also a symptom of phenylketonuria, which as discussed above is associated with a markedly elevated PE turnover [44] . Further, amphetamines, which have clinical utility in ADHD, are good ligands at trace amine receptors [2] . Of possible relevance in this aspect is modafanil, which has shown beneficial effects in ADHD patients [101] and has been reported to enhance the activity of PE at TAAR1 [102] . Conversely, methylphenidate, which is also clinically useful in ADHD, showed poor efficacy at the TAAR1 receptor [2] . In this respect it is worth noting that the enhancement of functioning at TAAR1 seen with Fig. (4) . Schematic summary of trace amine related changes suggested to occur in schizophrenia. For an explanation of abbreviations see Fig.  (3) . Boxed text in an enlarged font indicates an increase in enzyme activity or concentration, encircled text in a smaller font indicates a decrease in enzyme activity or concentration. Non-shaded TAAR indicates a receptor for which a polymorphism associated with schizophrenia has been suggested. ? -The initial suggestion of a schizophrenia associated polymorphism was not observed in a subsequent study. modafanil was not a result of a direct interaction with TAAR1 [102] .
More direct evidence has been obtained recently for a role of trace amines in ADHD. Urinary PE levels have been reported to be decreased in ADHD patients in comparison to both controls and patients with autism [103] [104] [105] . Evidence for a decrease in PE levels in the brain of ADHD patients has also recently been reported [4] . In addition, decreases in the urine and plasma levels of the PE metabolite phenylacetic acid and the precursors phenylalanine and tyrosine have been reported along with decreases in plasma tyramine [103] . Following treatment with methylphenidate, patients who responded positively showed a normalization of urinary PE, whilst non-responders showed no change from baseline values [105] . However, there did not appear to be a direct link between urinary PE levels and ADHD severity [105] . Phenylalanine administration alone does not appear to be beneficial to these patients [106] .
Direct evidence for altered AADC activity has been obtained from positron emission tomography studies of ADHD patients [107] , with increases in AADC reported to be correlated with symptom severity [108] . There is also evidence indicating an increased paternal transmission of AADC alleles in ADHD in an Irish population [109] . Further, the AADC gene maps to a region of chromosome 7p that was recently identified as a susceptibility locus for ADHD [110] .
Although these studies require replication, they support further investigation of the role of trace amines and their metabolic pathways in ADHD. In general, the results so far obtained seem to suggest that there may be a decrease in trace aminergic functioning, which may be normalized by currently available therapeutics. The reports of increased AADC activity correlating with disease severity, however, would seem to contradict such a hypothesis.
DRUG ABUSE/DEPENDENCE
Trace amines have also been suggested to play a role in the neural mechanisms underlying drug abuse and dependence. Indeed, as previously described, PE has been proposed to be an endogenous amphetamine [26, 49] . These historical observations are seemingly supported by the observations that amphetamines, along with a number of other drugs of abuse, are some of the more potent ligands at TAAR1 [2] . Caution is required, however. Although amphetamine is a ligand at TAAR1, it has previously been shown that amphetamine does not displace radiolabeled trace amines from their binding sites [111] .
Behavioral responses to PE also resemble those seen with amphetamine. Behavioral sensitization to PE has been shown to occur [112] and PE has been suggested to be involved in the neural mechanisms underlying reward and reinforcement [50, 113] . Experimental animals also self-administer PE [50, 113, 114] . Further, animals maintaining electrical selfstimulation show a decreased MAO inhibitor-induced elevation of PE [50] , indicating that stimulation is associated with altered PE metabolism. Such effects are consistent with PE mediating the behavioral phenotype induced by amphetamine. Differences have been observed, however, between the behavioral phenotypes induced by PE and amphetamine [50, 115] . In particular, exogenously administered PE does not induce aversive stimulus properties. In contrast, most drugs of abuse, including amphetamine, induce pronounced aversive stimulus properties [50] . Further, differences in amphetamine-and PE-induced selfstimulation have been noted [115] . While such observations do not preclude a role for PE and trace amines in inducing behavioral phenotypes associated with drugs of abuse and dependence, they do suggest a level of complexity beyond the initial hypothesis that PE acts as an endogenous amphetamine. It is also worth noting that PE brain levels have been suggested to require elevation above 70ng/g tissue in order for self stimulation properties to be observed [50] . Such levels are approximately 20-30 fold above normal trace amine levels [3] .
Trace amines have also been implicated in the abuse/dependence of other substances. The requirement for tyramine in order for Drosophila to develop sensitization to cocaine [116] has often been cited in recent years [2, 6, 43] . Considerable caution is required in generalizing speciesspecific results, however, in particular between vertebrates and invertebrates. In this aspect, it should be borne in mind that in invertebrates, trace amines serve a traditional neurotransmitter function [117] . Further, mammalian trace amine receptors appear to have evolved only following the divergence of vertebrates and invertebrates [1, 11, 30] . As such, studies conducted in invertebrates may be of limited relevance to elucidating the functional consequences and clinical utility of trace aminergic systems in mammals.
The previously described A1 allele of the D2 dopamine receptor, which is associated with an increased AADC activity [85] , has been suggested to be associated with an increased risk of alcoholism [84, 118] , although these results have been questioned [119] . Of interest in this respect are the independent reports of increased AADC activity seen in alcohol-dependent patients, as assessed by PET scans [120] . As described elsewhere, AADC is not rate limiting for monoamine neurotransmitter synthesis and changes in its activity do not appear to affect neurotransmitter levels. In contrast, levels of the trace amines are considerably changed in response to changes in AADC activity. Single nucleotide polymorphisms within the AADC gene have also been linked to nicotine dependence, at least in European populations [121] . The 7p11 chromosome region, which contains the AADC gene, was previously linked to smoking quantity [122] , whilst dopaminergic activity has been hypothesized to play a role in nicotine dependence [123] . Of interest in this respect, the A1 allele of the D2 receptor has also been frequently associated with nicotine dependence [84, [124] [125] [126] . Again, altered AADC activity can result in changes in dopaminergic activity via regulation of trace amine levels and their subsequent modulation of dopaminergic functioning.
In addition to alcoholism and nicotine dependence, the A1 allele of the D2 dopamine receptor has also been suggested to be a risk factor for a number of other addictions including those to psychostimulants [84, 127] , opioids [128] , polysubstance abuse [129] [130] [131] and gambling [132] in at least a subset of the population. Although such studies have not always been replicated (see [84] and references therein), they do raise the possibility that the allele may be a more generic risk factor for addiction/drug dependence, rather than acting in a substance-specific manner. An ethnic-and sexspecific association has also been reported between COMT haplotypes and nicotine dependence [133] . As described previously, O-methyl metabolites of monoamine neurotransmitters are particularly potent ligands at TAAR [2] . Two further drugs of abuse have been linked to trace amines in individual reports. γ-hydroxybutyric acid, the so called 'date rape drug' has also been suggested as a possible ligand for TAAR [43] . Finally, ∆ 9 -tetrahydrocannabinol has been shown to cause increases in central PE [100] .
ANOREXIA/EATING DISORDERS
Although few studies have been conducted, there is interest in the role of trace amines in anorexia and other eating disorders due to the close similarity between PE and amphetamine. Amphetamine has well documented anorectic effects [134] , an effect that can also be demonstrated with PE, and appears to be due to a decreased food intake [135] . Further, the TAAR1 protein is found in brain regions suggested to be involved in the control of appetite [6] . Finally, the ability to displace amphetamine from its binding sites within the brain has been shown to correlate with anorectic activity [136] . The degree with which such binding sites overlap with the more recently identified TAAR receptors requires further study. Although trace amines, notably tyramine and octopamine, have been documented to regulate feeding behavior in invertebrates [137] , this again is likely to be of limited relevance to mammalian species.
AFFECTIVE DISORDERS
Trace amines have received much attention with respect to a pathological relevance in the etiology of affective disorders. Once again, most of this attention has focused on a role for PE. Unlike other disorders, however, a much more cohesive theory has been put forth, whereby deficits in PE functioning/turnover are associated with depression, whilst elevated PE functioning is associated with mania [5, 6, 44, 138] . Indeed, trace amines have been suggested to function to maintain mental functions within "normal" limits [44] , a hypothesis strikingly similar to the neuromodulator hypothesis for trace amine functioning at the cellular level [3, 12] .
Older studies examining the levels of PE in a variety of body fluids have in general supported this so-called PE hypothesis. These studies have been comprehensively reviewed elsewhere [18, 19] , and the reader is referred to these tabulations for further details. In summary, the most robust changes observed are a decrease in urinary, plasma and CSF PE and/or phenylacetic acid [19, [139] [140] [141] . Adding further weight to the theory, a number of clinically effective antidepressant treatments (including tricyclic antidepressants, MAO inhibitors and electroconvulsive shock therapy) have been shown to elevate PE levels/functioning [142] [143] [144] [145] , whilst phenelzine has been shown to be metabolized to PE [146] . Further, chronic treatment of experimental animals with antidepressants has been reported to decrease β-adrenergic receptor number [147] , an effect mirrored by chronic PE administration [148] . Finally reserpine, which can precipitate episodes of depression [149] , also decreases central trace amine levels [150] .
More recently, MAO-B knock-out mice, whose only documented neurochemical change is a pronounced elevation of central PE, have been shown to exhibit a behavioral phenotype that is indistinguishable from that induced by clinically effective antidepressants [88] . It has also been suggested that the antidepressant effects of exercise are due to an exercise-induced elevation of PE [151] . Two studies have directly sought to elevate endogenous PE levels in patients with depressive disorders. In the first, a combination of (-)deprenyl to inhibit MAO-B and phenylalanine, the precursor of PE, was reported to be beneficial in 70% of patients [152] . A more recent study reported a decrease in depressive symptomatology in 60% of patients treated with either L-phenylalanine or PE [153] . Such results are consistent with earlier studies where phenylalanine was reported to be as effective as imipramine in treating depression [154] .
Other trace amines, notably tyramine [43, 155] , tryptamine [43, 58] and octopamine [155] , have also been suggested to play a role in depressive symptomatology. Few additional studies have been performed however. TAAR appears to be appropriately distributed in the CNS to play a role in the control of affect, receptors having been localized in particular to the amygdala [1] . Genetically, a susceptibility locus for bipolar disorder has been suggested on chromosome 6q22 [156] [157] [158] , close to the chromosomal location of all TAAR. Variants in the AADC gene have also been suggested to be linked to both unipolar and bipolar disorder [159] , although such results are not without controversy. In a follow-up study, the original association could not be replicated, although there was evidence for a paternal transmission that may increase susceptibility [160] . An association between bipolar disorder and COMT polymorphisms has also recently been reported [161] . Thus, as was seen in schizophrenia, there is evidence of genetic susceptibility factors, which are linked to normal trace amine metabolic pathways playing a role in affective disorders.
The above studies are summarized in Fig. (5) . Taken together, the above described studies provide a fairly uniform view for a deficit of trace aminergic functioning being associated with depressive disorders in at least a subset of patients. The recent discovery of a family of TAAR provides a new target to which novel molecules can be designed with a view to investigating their potential utility for the treatment of affective disorders.
MIGRAINE/CLUSTER HEADACHE
Suggestions of a potential link between trace amines and the etiology of pathological headache, in particular migraine, have long circulated in the scientific literature. Initially proposed by Hanington [162] , the hypothesis garnered considerable support from the observations that foods known to precipitate migraine attacks in susceptible individuals contain high levels of trace amines [163] . In particular, chocolate contains high levels of PE, whilst aged cheeses and red wine have a high tyramine content [163] [164] [165] [166] . Such foods are also known to increase blood pressure and this has also been suggested to be the causative effect in precipitating attacks [167] . In this respect, it is interesting to note that trace amine receptors are present both in the kidney [1] and vasculature [168] . The basis behind individual susceptibility is not understood and early suggestions that migraine attacks may be due to a deficit in MAO-B [162] have not generally been supported clinically [169] , although a decreased platelet MAO activity has been reported to be associated w i t h menstrual migraine [170] . Further, it has been suggested that conversion of tyramine to octopamine (see Fig. 1 ) is required for precipitation of migraine attacks [171] .
Given the frequency with which links between migraine and elevated trace amines continue to be cited [5, 6, 43, 172, 173] , it is surprising to note how little evidence supportive of such a link is available. Elevations in plasma octopamine and synephrine have been reported in patients suffering migraines in comparison to controls [174] , while no difference was observed in plasma tyramine levels [174] . This study was recently extended, with elevated octopamine reported to be associated with migraine with aura patients, whilst in patients suffering migraine without aura synephrine was significantly elevated [175] . Of possible interest, it was recently reported that gelatin capsules used during oral administration of placebos during clinical trials contain high levels of tyramine [176] , possibly explaining reports of headache amongst migraineurs following placebo administration. Similarly a single study has reported elevations in tyramine, octopamine and synephrine in both the plasma and platelets of patients with cluster headaches [174] , although no differences were noted between patients in the active and remission phases. Of possible relevance are suggestions that cluster headaches are hypothalamic in origin [177, 178] , the hypothalamus containing the highest concentrations of octopamine [3] . In the one study conducted, no evidence of a genetic link between cluster headache and trace amine receptors was found in the two families examined [179] . Similarly there was no change in AADC allele frequency observed in migraine patients compared to controls [180] .
In summary, although an attractive hypothesis on the basis of food-induced migraine, there is little direct evidence at present supporting a role of trace amines in pathological headache. Evidence for changes in monoamine neurotransmitter metabolism has led to suggestions that such headaches are due to an imbalance between excitatory and inhibitory neurotransmitters [181] . Although trace amines may be involved in the generation of such an imbalance by virtue of their suggested role in maintaining basal neuronal tone within defined physiological limits [3] , additional studies are required. 
STRESS/ANXIETY DISORDERS
Stress is a possible precipitating factor for acute schizophrenic episodes. Due to the possible role of PE in schizophrenia, Paulos and Tessel [182] investigated the excretion of PE following stressful experiences. Using parachuting as the stress-inducer, it was reported that urinary PE excretion was markedly increased in the hours post parachuting. These changes were not correlated with changes in urinary pH or creatinine excretion [182] , suggesting that the results do not merely represent a global change in metabolism. Although intriguing, replication studies do not appear to have been attempted. PE has also been proposed to be an endogenous anxiogen in experimental animals [183] . At doses below those usually required to elicit amphetamine-like responses, PE was reported to cause behavioral changes indicative of an anxiogen. Further, the effects were prevented by the anxiolytic agent diazepam [183] . In agreement with these findings, genetic deficiency in MAO-B was associated with an exaggerated stress response in mice [88] . Biochemically, these animals were notable for a pronounced elevation in PE, with few consistent changes in other biogenic amines [88] .
As previously described, N,N-dimethyltryptamine (DMT), a known hallucinogen produced endogenously, has historically been suggested to play a role in the etiology of schizophrenia. These studies have recently been re-interpreted. At non-hallucinogenic doses, DMT elicited responses consistent with an anxiolytic agent [59] , leading to a suggestion that DMT and other endogenous tryptamines are endogenous anxiolytic compounds [59] . Here the increased DMT production associated with schizophrenia is regarded as an attempt by the body to regain emotional control [59] .
Finally, endogenous β-carbolines are putative ligands at one or more TAAR [10] . These agents also interact with benzodiazepine binding sites [184, 185] and have been suggested to play both anxiogenic and anxiolytic roles [186] . Whilst an interaction of endogenous β-carbolines with TAAR requires definitive demonstration, such a demonstration would classify TAAR as a target to which novel anxiolytic agents can be designed.
REYE'S SYNDROME
Reye's Syndrome has been defined as an unexplained, non-inflammatory encephalopathy, which is associated with elevated aspartate or alanine aminotransferases, hyperammonemia and fatty degeneration of the liver and mitochondrial dysfunction in children [187] . Such mitochondrial dysfunction could cause pronounced changes in endogenous trace amine levels, as metabolism via MAO would be expected to be compromised. Although there has been much conjecture regarding the possible role of aspirin in initiating Reye's Syndrome [188] , a definitive cause remains elusive. Octopamine and tryptamine have been suggested to play a role in hepatic encephalopathy [43, 189, 190] , whilst postmortem brain octopamine levels have been reported to be elevated 700% in Reye's Syndrome patients [191] . The cause and effect relationship of such observations requires clarification, although it is interesting that similarities have been noted between tyramine-induced coma in experimental animals with concomitant liver damage and the coma associated with Reye's Syndrome [192] . Evidence has also been presented for markedly elevated tyramine levels in patient urine and plasma [193] . Of note, the increased tyramine levels were reported to be correlated to the subsequent length of coma and hyperammonemia [193] .
Such elevated tyramine levels would be expected to also result in an increase in octopamine levels (see Fig. 1 ). Whether correction of trace amine functioning alone, without addressing the underlying hepatic failure and mitochondrial dysfunction, would be beneficial in Reye's Syndrome patients requires further investigation.
EPILEPSY
Administration of high doses of PE have been shown to induce seizure activity in mice [194] . Such epileptiform activity was antagonized by standard benzodiazepine antiepileptics in a manner suggesting that the high doses of PE interacted with the GABAergic system [194] . In this respect it is interesting to note that PE and tyramine were recently demonstrated to modulate GABAergic responses [22] in a manner similar to that previously described for dopaminergic and noradrenergic responses [3] . Neither PE, tyramine nor octopamine appear to interact directly with flunitrazepam binding sites however [195] . β-carbolines, which are known to decrease seizure threshold, have been thought to do so due to an interaction with benzodiazepine binding sites associated with GABA receptors [184, 185, 196] . As described previously, endogenous β-carbolines have been suggested as putative endogenous ligands at one or more TAAR [10] . As such, there are preliminary indications suggesting an investigation of a role for TAAR in the genesis and control of seizure activity may be warranted.
CONCLUDING STATEMENTS
As can be seen from the preceding sections, although little is known about the basic functioning of the trace aminergic system, there is a large body of literature linking alterations in trace amines and their metabolism to a variety of clinical conditions. As progress continues to be made in elucidating the molecular mechanisms of trace amine functioning, selective ligands for each TAAR will be developed. The first such ligands for TAAR have recently been described [31] and these will likely aid considerably in the elucidation of the basic mechanisms of trace amines and their clinical relevance. Further, it is becoming apparent that existing therapeutics and drugs of abuse may interact with TAAR, either directly [2] or indirectly [102] , providing an additional explanation for the observed clinical effects of such compounds. The high species variation present in trace amine receptors is, however, a considerable complicating factor. This high variation, along with the proposed speciesdependant relevance of TAAR, makes generalizations of results from animal studies to humans difficult. The discovery of TAAR has also provided an additional target for the modification of central neuronal processes. The proposed function of trace amines in maintaining central neuronal functioning within defined physiological limits means that a primary deficit in trace aminergic functioning may not be required for TAAR ligands to be of therapeutic relevance. For example, although not discussed here, trace amine ligands are also likely to be useful in disorders such as Parkinson's disease. Here a synthetic ligand that mimics the potentiation of dopaminergic responses observed following elevation of PE levels could realistically be expected to provide symptomatic relief. In summary, the discovery of the TAAR family of receptors has rejuvenated interest in the trace amines, an endogenous family of compounds with therapeutic implications in a number of human neurologic and psychiatric conditions.
